Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant
PUBT · 06/11 19:28
Share
Listen to the news
- Aethlon Medical outlined progress for its Hemopurifier blood-filtration platform targeting cancer, viral threats, and transplant-related applications.
- Australian oncology study: cohorts 1-2 complete; cohort 3 open; first patient treated in June 2026; no dose-limiting toxicities reported.
- Upcoming catalysts flagged within 6-9 months, including central lab readouts on extracellular vesicle removal, CD8 T-cell changes, and safety.
- Corporate overview cited about $5 million cash at March 31, 2026; no outstanding debt; about 2,400,000 shares outstanding as of June 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved